
Clinical TrialAug 13, 2026, 07:37 AM
Clearmind Medicine CMND-100 AUD trial advances to Parts B & C
AI Summary
Clearmind Medicine Inc. announced that its independent DSMB has unanimously approved advancing the Phase I/II clinical trial for CMND-100 to Parts B and C. This follows the successful completion of Part A, where CMND-100 achieved its primary safety endpoint, demonstrating a favorable safety and tolerability profile in healthy participants. Parts B and C will evaluate CMND-100 in patients with Alcohol Use Disorder and healthy participants, marking a significant step towards a potential new treatment option.
Key Highlights
- Independent Data and Safety Monitoring Board (DSMB) approved advancing CMND-100 clinical trial.
- Trial for Alcohol Use Disorder (AUD) patients progresses to Parts B and C.
- Part A successfully met its primary safety endpoint, showing favorable safety and tolerability.
- Part B will evaluate CMND-100 in AUD patients for the first time.
- Part B will enroll two cohorts of six patients receiving 80 mg and 160 mg doses.
- Part C will evaluate CMND-100 at a fixed daily dose of 160 mg over five days in healthy participants.
- CMND-100 is a non-hallucinogenic neuroplastogen-derived therapeutic for AUD.
Price Impact
More from CMND